FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $398.32M
Company Location Date Amt. (M) Details
Adenosine

Therapeutics LLC

 Charlottesville, Va. 11/30/07 $4.5 Adenosine raised $4.5M from ATEL Ventures Inc.
Ambit Biosciences Corp. San Diego 11/13/07 $49.3 Ambit raised $49.3M in a Series D round led by Apposite Capital LLP; other participants were MedImmune Ventures Inc., OrbiMed Advisors LLC, Radius Ventures LLC, NovaQuest and Horizon Technology Finance LLC, as well as Perseus-Soros Biopharmaceutical Fund LP, ForwardVentures, Avalon Ventures, Roche Venture Fund, GIMV, Jov-CMDF and Genechem
Anaptys Biosciences Inc. La Jolla, Calif. 11/19/07 $33.9 Anaptys raised $33.9M in a Series B financing led by Novo A/S, with participation from additional investors Frazier Healthcare Ventures, Alloy Ventures, Avalon Ventures, Numenor Ventures, WS Investment Co. and Anaptys board member Nick Lydon
Antisense Pharma GmbH Regensburg, Germany 11/8/07 €27 ($38) Antisense Pharma raised $38M from MIG Funds 5, the fifth VC fund of German firm MIG Verwaltungs AG
Atlantic Healthcare Ltd. Cambridge, UK 11/14/07** £1 ($2.1) Atlantic Healthcare raised $2.1M in a private round
BIND Biosciences Inc. Cambridge, Mass. 11/27/07 $16 BIND raised $16M in a Series B round; investors were Polaris Venture Partners, Flagship Ventures, ARCH Ventures and NanoDimension
BioVex Inc. Woburn, Mass. 11/15/07 $13 BioVex raised $13M in the second close of its Series E financing led by Triathlon Medical Ventures
Caprotec Bioanalytics GmbH Berlin 11/29/07 €4.5 ($6.6) Caprotec raised $6.6M from the VC Fonds Berlin GmbH, which is managed by the IBB Beteiligungsgesellschaft, the ERP Startfonds and private investors
Clarus Therapeutics Inc. Northbrook, Ill. 11/27/07 $8 Clarus raised $8M in a Series C financing led by H.I.G. Ventures, with participation from Thomas, McNerney & Partners
Excaliard Pharmaceuticals Inc. Encinatas, Calif. 11/27/07 $15.5 Excaliard raised $15.5M in a Series A round led by Alta Partners, ProQuest Investments and RiverVest Venture Partners
Fate Therapeutics Seattle 11/30/07 $12 Fate raised $12M in a Series A round from ARCH Venture Partners, Polaris Venture Partners, Venrock Associates and OVP Venture Partners
Formac Pharmaceuticals NV Leuven, Belgium 11/7/07 €1.7 ($2.5) Formac raised $2.5M through investments by Allegro Investment Fund, Hunza Ventures, Gemma Frisius Fonds K.U. Leuven II and Vinnof
F-star Vienna, Austria 11/28/07 €3 ($4.5) F-star raised $4.5M in a second closing of a Series A financing, bringing the total raised to €9M
HemaQuest Pharmaceuticals Newton, Mass. 11/1/07 $20 HemaQuest raised $20M in a Series A round; investors included De Novo Ventures, Forward Ventures and Lilly Ventures
HistoRx Inc. New Haven, Conn. 11/16/07 $6 HistoRx raised $6M in a Series B round led by Brook Venture Partners; other participants were Navigator Technology Ventures, The Roche Venture Fund, Commons Capital and Maven Capital
iCo Therapeutics Inc. Vancouver, British Columbia 11/1/07 $1.8 iCo Therapeutics amended its agreement with Beanstalk Capital Ltd. for a brokered private placement worth $1.8M; it consists of 1.8M iCo subscription receipts priced at 98 cents each; lead agent Canaccord Capital Corp. will have the option to an additional 1M receipts to cover over allotments
Lead Therapeutics Inc. San Bruno, Calif. 11/5/07 $17 Lead raised $17M in a Series A round led by Pappas Ventures and ProQuest Investments, with participation also by Mustang Ventures
Novalar Pharmaceuticals Inc. San Diego 11/1/07 $30 Novalar raised $30M in a Series D financing led by New Enterprise Associates; other investors were Domain Associates, SR One and Montreux Equity Partners
MiddleBrook Pharmaceuticals Inc. Germantown, Md. 11/8/07 $7.5 MiddleBrook raised $7.5M through an agreement with Deerfield Management that involves the sale of certain assets relating to its cephalexin business, excluding cephalexin Pulsys
Plasticell Ltd. London 11/28/07** £0.25 ($0.517) Plasticell raised $517,404 from the Capital Fund
Protein Sciences Corp. Meriden, Conn. 11/8/07 $1 Diamyd Medical invested $1M in the form of a convertible note in Protein Sciences
SantoSolve AS Oslo, Norway 11/7/07 $7 SantoSolve raised $7M in a private financing round; investors included DnB NOR, Gezina AS, Glastad Invest AS, Teknoinvest AS and InnovationsKapital
Sloning BioTechnology GmbH Puchheim, Germany 11/6/07 €4.7 ($6.8) Sloning raised $6.8M in the first closing of a Series E round; investors were LBBW Venture Capital GmbH, HBM BioVentures, KfW Banken-gruppe and Deutsche Effecten-und Wechsel-Beteiligungsgesellschaft AG
Syntaxin London 11/7/07** £16 ($33.3) Syntaxin raised $33.3M in a second private round co-led by SR One, the venture capital arm of GlaxoSmithKline plc and Life Science Partners;Johnson & Johnson Development Corp., Quest forGrowth and Abingworth Management also participated
Tranzyme Pharma Research Triangle Park, N.C. 11/1/07 $20 Tranzyme raise $20M in a round led by H.I.G.Ventures, Thomas, McNerney & Partners, Quaker BioVentures and BDC Venture Capital
Vaxart Inc. San Francisco 11/15/07 $3.3 Vaxart raised $3.3M in the Series A round
Vitreoretinal Technologies Inc. Irvine, Calif. 11/28/07 $8.8 Vitreoretinal Technologies closed an $8.8M Series A financing with De Novo Ventures and a group of private investors
Xenome Ltd. Brisbane, Australia 11/27/07 $10 Xenome raised $10M through Queensland BioCapital Funds, Amylin Pharmaceuticals Inc. and Innovis Investment Partners
Yaupon Therapeutics Inc. Radnor, Pa. 11/26/07 $14.5 Yaupon closed a $14.5M Series C round led by Vivo Ventures, with participation from Palo Alto Investors LLC and private investors
Znomics Inc. Portland, Ore. 11/28/07 $4.9 Znomics raised $4.9M in a private financing
Notes:

Currency conversions are based on exchange rates at the time of the deal.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed.